HealthFinancial Timesabout 2 hours ago
LEQEMBI Autoinjector Matches IV Efficacy in Alzheimer's
1 min read
Clinical data presented at AAIC 2026 shows LEQEMBI's subcutaneous autoinjector delivers similar efficacy and safety to the IV formulation for early Alzheimer's disease. The company announcement reports the autoinjector offers a more convenient administration option for patients.
Level
Hype check
Tap to vote and see what everyone thinks.
Summary by ByteBrief
